


CLAIM AMENDMENTS

Listing of Claims:

Claims 1-33 (canceled)


Claim 34 (currently amended): A macrocyclic compound of the formula (1):



and it's its pharmaceutically acceptable salts,



wherein

Fragment A₁ is:




wherein

Y is selected from the group consisting of



and


X₁ is -CH-, -(CH₂)₂- or -(CH₂)₃-;
when X₁ is -(CH₂)₂- or -(CH₂)₃-, R₁ is absent;
when X₁ is -CH-, R₁ is a radical independently selected from the group
consisting of



Fragment A₂ is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert- butoxyproline, *L*-4-tert-butoxyproline; or

(2-ii)




wherein

X_2 is $-\text{CH}-$, $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$;

when X_2 is $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$, R_2 is absent;


when X_2 is $-\text{CH}-$, R_2 is a radical independently selected from the group consisting of



Fragment A₃ is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert- butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)




wherein

X_3 is $-CH-$, $-(CH_2)_2-$ or $-(CH_2)_3-$;


when X_3 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_3 is absent;

when X_3 is $-CH-$, R_3 is a radical independently selected from the group consisting of




W₁ to W₁₆ are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;

Fragment T is a radical selected from the group consisting of:



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A₁ of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A₃ of formula (1).

Claim 35 (currently amended): A macrocyclic compound of the formula (1):




and it's its pharmaceutically acceptable salts,

wherein



Fragment A₁ is:

(1-i)



wherein


Y is selected from the group consisting of



X₁ is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X₁ is -(CH₂)₂- or -(CH₂)₃-, R₁ is absent;


when X_1 is -CH-, R_1 is a radical independently selected from the group consisting of



Fragment A₂ is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert- butoxyproline, *L*-4-tert-butoxyproline; or

(2-ii)




wherein

X_2 is $-CH-$, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_2 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_2 is absent;


when X_2 is $-CH-$, R_2 is a radical independently selected from the group consisting of



Fragment A₃ is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert- butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)




wherein


X_3 is $-\text{CH}-$, $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$;

when X_3 is $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$, R_3 is absent;


when X_3 is $-\text{CH}-$, R_3 is a radical independently selected from the group consisting of



W₁ to W₁₆ are each selected from the group consisting of hydrogen, and a compatible protecting group chosen from:




Fragment T is a radical selected from the group consisting of:



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A₁ of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A₃ of formula (1).


Claim 36 (currently amended): A macrocyclic compound of the formula (1):



and it's its pharmaceutically acceptable salts,

wherein

Fragment A₁ is:




wherein

X₁ is -CH-, -(CH₂)₂- or -(CH₂)₃-;

when X₁ is -(CH₂)₂- or -(CH₂)₃-, R₁ is absent;


when X₁ is -CH-, R₁ is a radical independently selected from the group consisting of:



Fragment A₂ is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline; or

(2-ii)




wherein

X_2 is $-\text{CH}-$, $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$;

when X_2 is $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$, R_2 is absent;

when X_2 is $-\text{CH}-$, R_2 is a radical independently selected from the group


consisting of



Fragment A₃ is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline; or

(3-ii)




wherein

X_3 is $-\text{CH}-$, $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$;


when X_3 is $-(\text{CH}_2)_2-$ or $-(\text{CH}_2)_3-$, R_3 is absent;

when X_3 is $-\text{CH}-$, R_3 is a radical independently selected from the group consisting

of



Fragment T is a radical selected from the group consisting of:



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A₁ of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A₃ of formula (1).